Tuesday October 17th 2017

Striking a Nerve: Docs, Patients Fume Over Lemtrada Snub

(MedPage Today) — The FDA’s surprise rejection of alemtuzumab for relapsing-remitting multiple sclerosis has generated outrage among investigators in the drug’s clinical trials as well in the MS patient community. (Source: MedPage Today Public Health)

View original:

Striking a Nerve: Docs, Patients Fume Over Lemtrada Snub

Leave a Comment

More from category

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS

Roche announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms [Read More]

All you need to know about dysesthesia
All you need to know about dysesthesia

Dysesthesia is a painful, itchy sensation, often associated with multiple sclerosis (MS). Learn more about the symptoms [Read More]

Medical News Today: All you need to know about dysesthesia
Medical News Today: All you need to know about dysesthesia

Dysesthesia is a painful, itchy sensation, often associated with multiple sclerosis (MS). Learn more about the symptoms [Read More]

MRI brain scans can reveal MS risk in children before clinical symptoms appear
MRI brain scans can reveal MS risk in children before clinical symptoms appear

By the time multiple sclerosis (MS) is diagnosed in children, it may be difficult to prevent the disabilities and [Read More]

Open Enrollment for Marketplace and Medicare Plans
Open Enrollment for Marketplace and Medicare Plans

/About-the-Society/News/Open-Enrollment-for-Marketplace-and-Medicare-Plans [Read More]